skip to main content, skip to Quick links, or skip to Search

main content

Internal Medicine

Multi-institutional clinical study for dogs with non-azotemic primary glomerular disease

Purpose:

To evaluate the effects of titrating up doses of enalapril on maximal reductions in urine protein excretion. The current recommended enalapril dose was established using 75% suppression of ACE activity as the desired pharmacodynamic end-point. However, recent studies in people suggest that higher doses may be required for maximal reduction in urine protein excretion and may dramatically improve patient survival.

Study Design:

Participants will be randomized into either a standard enalapril dose or an up-titrated enalapril dose group. Dogs in the standard dose group will have follow-up visits at 12, 24 and 36 weeks. Dogs in the up-titrated dose group will have the dose of enalapril gradually increased over 1-2 visits (weeks 3 and 6) until the maximal reduction in urine protein: creatinine ratio is noted, then follow-up visits at 12, 24 and 36 weeks.

Location:

All initial and follow-up visits will be performed at the NCSU Randall B. Terry, Jr. Companion Animal Veterinary Medical Center.

Eligibility:

Exclusions:

Study Incentives:

Contact:

Tonya Harris: 919-513-6206, tonya_harris@ncsu.edu

Page last updated September 04, 2013